About US
Contact us
-
GSK and Adaptimmune expand cancer immunotherapy allianceGlaxoSmithKline (GSK) has expanded the collaboration agreement with Adaptimmune to accelerate development of the latter's lead clinical cancer programme, an affinity enhanced T-cell immunotherapy (GSK2016/2/5
-
AstraZeneca acquires 55% stake in Acerta Pharma for $4bnAstraZeneca has completed the acquisition of 55% stake in Acerta Pharma, a privately-owned biopharmaceutical firm, for $4bn. Acerta Pharma has operations in Oss, the Netherlands and several US sites,2016/2/5
-
Can fast-growing Eliquis overtake J&J's Xarelto? Bristol's execs think soEliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has seriously picked up the pace lately, rocketing to the top of Bristol-Myers Squibb's ($BMY) sales charts. And2016/2/4
-
Merck treads water in Q4 as Keytruda helps offset Remicade sufferingMerck & Co. ($MRK) took a one-two punch in the fourth quarter. Revenue from two top-selling franchises--JanuviaandRemicade--slid, dragging overall sales below analyst estimates at $10.2 billion. O2016/2/4
-
EMA validates Gilead’s Type II variation application for Truvada to reduce risk of HIV-1 infectionThe European Medicines Agency (EMA) has validated Gilead Sciences' Type II variation application for once-daily Truvada to reduce the risk of sexually acquired HIV-1 infection among uninfected adults2016/2/3
-
Allergan and AstraZeneca to develop ATM-AVI for antibiotic-resistant gram-negative infectionsIrish drug-maker Allergan has entered into a global agreement with UK's AstraZeneca to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam.2016/2/3
-
New data boosts Novo against Sanofi in insulin-market fightNovo Nordisk ($NVO) has some new data in hand that could help a safety advantage make its way onto the label of new drugTresiba--and win it points against heavyweight rival Sanofi ($SNY). In a recent2016/2/2
-
Gilead scheduling meet-up with Massachusetts AG over hep C pricing: GlobeGilead Sciences ($GILD) is scheduling a meeting with Massachusetts Attorney General Maura Healey after last week's threat of legal action against the company. And though some legal experts doubt Heale2016/2/2
-
Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVieIndustry watchers have long been speculating on how Merck would take on heavyweights Gilead ($GILD) and AbbVie ($ABBV) when it priced its new hep C regimen. And now, they have their answer: Undercut t2016/2/1
-
Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcomaJapan'sEisaigot a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced to the point where surgery is2016/2/1